<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "cytarabine inj VIAL">
<dose><value>50</value>
<value>40</value>
<value>30</value>
<value>2000</value>
<value>1000</value>
<value>3000</value>
<value>1500</value>
<value>20</value>
<value>75</value>
</dose>
<route><value>INTRATHECAL</value>
<value>IV</value>
<value>SC</value>
</route>
<strength><value>100 mg</value>
<value>100 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
<value>TWO TIMES WEEKLY</value>
<value>Q12H</value>
<value>DAILY</value>
</frequency>
<instruction><value>for 4 doses.</value>
<value>Administer dose diluted in 500 mL 0.9% sodium chloride over 2 hours.</value>
<value>for 2 doses. Administer dose diluted in 250 mL D5W over 3 hours.</value>
<value>for 4 doses. Administer dose diluted in 500 mL D5W over 2 hours.</value>
<value>for 2 doses. Administer dose diluted in 500 mL 0.9% sodium chloride over 3 hours.</value>
<value>for 2 doses. Administer dose diluted in 500 mL D5W over 3 hours.</value>
<value>for 2 doses. Administer dose diluted in 500 mL 0.9% sodium chloride over 2 hours.</value>
<value>for 4 doses. Administer dose diluted in 500 mL D5W over 3 hours.</value>
<value>for 4 days.</value>
</instruction>
<volume><value>1 mL</value>
<value>10 mL</value>
<value>20 mL</value>
</volume>
<units><value>mg</value>
<value>mg/m2</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Acute Lymphocytic Leukemia. </value>
<value>Acute Lymphocytic Leukemia. Administered in combination with methotrexate and hydrocortisone sodium succinate as a single intrathecal injection.</value>
<value>Lymphoma. Consideration towards prophylaxis of occular toxicity with dexamethasone eye drops/ointment.</value>
<value>Acute Lymphoblastic Lymphoma or Leukemia. Consideration towards prophylaxis of occular toxicity with dexamethasone eye drops/ointment.</value>
<value>Primary CNS Lymphoma (Transplant Eligible). Consideration towards prophylaxis of occular toxicity with dexamethasone eye drops/ointment.</value>
<value>Secondary CNS Lymphoma (Transplant Eligible). Consideration towards prophylaxis of occular toxicity with dexamethasone eye drops/ointment.</value>
<value>Primary CNS Lymphoma (Transplant Ineligible). Consideration towards prophylaxis of occular toxicity with dexamethasone eye drops/ointment.</value>
<value>Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Treatment for 10 days.</value>
<value>Leukemia; CALGB Late Intensification</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3368</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3365</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Discontinued.</value>
<value>Formulary.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>